Anders Berglund

Dr. Anders Berglund

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Magnetic Resonance Imaging
Verified
Journal Article
Closed access
VKVirendra Kumar
Virendra Kumar
YGYuhua Gu
Yuhua Gu
SBSatrajit Basu
Satrajit Basu
ABAnders Berglund
Anders Berglund
SESteven A. Eschrich
Steven A. Eschrich
RGRobert Gillies
Robert Gillies

1 October 2001 in Chemometrics and Intelligent Laboratory Systems
Verified
Journal Article
Closed access
SWSvante Wold
Svante Wold
JTJohan Trygg
Johan Trygg
ABAnders Berglund
Anders Berglund
HAHenrik Antti
Henrik Antti

1 February 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
JSJacob G Scott
Jacob G Scott
ABAnders Berglund
Anders Berglund
MSMichael J Schell
Michael J Schell
IMIvaylo Mihaylov
Ivaylo Mihaylov
WFWilliam J Fulp
William J Fulp
JTJavier F Torres-Roca
Javier F Torres-Roca

24 October 2012 in Scientific Reports
Verified
Journal Article
Open access
JMJane L. Messina
Jane L. Messina
DFDavid A. Fenstermacher
David A. Fenstermacher
SESteven Eschrich
Steven Eschrich
XQXiaotao Qu
Xiaotao Qu
ABAnders Berglund
Anders Berglund
JMJames Mule
James Mule
We have interrogated a 12-chemokine gene expression signature (GES) on genomic arrays of 14,492 distinct solid tumors and show broad distribution across different histologies. We hypothesized that this 12-chemokine GES might accurately predict a unique intratumoral immune reaction in stage IV (non-locoregional) melanoma metastases. The 12-chemokine GES predicted the presence of unique, lymph node-like structures, containing CD20+ B cell follicles with prominent areas of CD3+ T cells (both CD4+ and CD8+ subsets). CD86+, but not FoxP3+, cells were present within these unique structures as well. The direct correlation between the 12-chemokine GES score and the presence of unique, lymph nodal structures was also associated with better overall survival of the subset of melanoma patients. The use of this novel 12-chemokine GES may reveal basic information on in situ mechanisms of the anti-tumor immune response, potentially leading to improvements in the identification and selection of melanoma patients most suitable for immunotherapy.

19 October 2015 in Oncogene
Verified
Journal Article
Open access
PDF file
MSMatthew Schabath
Matthew Schabath
EWE A Welsh
E A Welsh
WFW J Fulp
W J Fulp
LCL Chen
L Chen
JTJ K Teer
J K Teer
ABA A Beg
A A Beg
While mutations in the KRAS oncogene are among the most prevalent in human cancer, there are few successful treatments to target these tumors. It is also likely that heterogeneity in KRAS-mutant tumor biology significantly contributes to the response to therapy. We hypothesized that the presence of commonly co-occurring mutations in STK11 and TP53 tumor suppressors may represent a significant source of heterogeneity in KRAS-mutant tumors. To address this, we utilized a large cohort of resected tumors from 442 lung adenocarcinoma patients with data including annotation of prevalent driver mutations (KRAS and EGFR) and tumor suppressor mutations (STK11 and TP53), microarray-based gene expression and clinical covariates, including overall survival (OS). Specifically, we determined impact of STK11 and TP53 mutations on a new KRAS mutation-associated gene expression signature as well as previously defined signatures of tumor cell proliferation and immune surveillance responses. Interestingly, STK11, but not TP53 mutations, were associated with highly elevated expression of KRAS mutation-associated genes. Mutations in TP53 and STK11 also impacted tumor biology regardless of KRAS status, with TP53 strongly associated with enhanced proliferation and STK11 with suppression of immune surveillance. These findings illustrate the remarkably distinct ways through which tumor suppressor mutations may contribute to heterogeneity in KRAS-mutant tumor biology. In addition, these studies point to novel associations between gene mutations and immune surveillance that could impact the response to immunotherapy.

1 September 2004 in The Plant Cell
Verified
Journal Article
Open access
PDF file
JSJarmo Schrader
Jarmo Schrader
JNJeanette Nilsson
Jeanette Nilsson
EMEwa Mellerowicz
Ewa Mellerowicz
ABAnders Berglund
Anders Berglund
PNPeter Nilsson
Peter Nilsson
GSGöran Sandberg
Göran Sandberg
Plant growth is the result of cell proliferation in meristems, which requires a careful balance between the formation of new tissue and the maintenance of a set of undifferentiated stem cells. Recent studies have provided important information on several genetic networks responsible for stem cell maintenance and regulation of cell differentiation in the apical meristems of shoots and roots. Nothing, however, is known about the regulatory networks in secondary meristems like the vascular cambium of trees. We have made use of the large size and highly regular layered organization of the cambial meristem to create a high-resolution transcriptional map covering 220 μm of the cambial region of aspen (Populus tremula). Clusters of differentially expressed genes revealed substantial differences in the transcriptomes of the six anatomically homogenous cell layers in the meristem zone. Based on transcriptional and anatomical data, we present a model for the position of the stem cells and the proliferating mother cells in the cambial zone. We also provide sets of marker genes for different stages of xylem and phloem differentiation and identify potential regulators of cambial meristem activity. Interestingly, analysis of known regulators of apical meristem development indicates substantial similarity in regulatory networks between primary and secondary meristems.